Here is COVID good news: It’s jumpstarted biomedical innovation

unnamed file

As we look back at the past few months, I see three lessons that health care researchers can take from our experience so far:

More collaboration. In nearly every case, meaningful progress against Covid-19 has been the result of multiple organizations working together with a unified mission. While partnerships have long been a facet of drug development, the intensity and scale of recent collaboration is unprecedented.

Rethink clinical trial design. Patients frequently cite barriers to access as a reason they don’t participate in clinical trials. In cancer research, for instance, more than half of patients don’t have a trial available to them at a nearby institution.


The widespread adoption of telehealth services spurred by recent social distancing measures is a significant step forward, as it allows geographically diverse patients to access trials where clinical sites aren’t available.

Related article:  Video: Inside the quest to truly understand the living cell
Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

Better integration of digital technologies… Digital solutions in clinical trials continue to rapidly evolve, and it is the pharmaceutical industry’s responsibility to lead the way in implementing them. It is also up to us to communicate the benefits these tools can offer to help overcome status quo biases that may hinder progress. For instance, we found that the clinical trial sites that implemented a cloud-based system enrolled 23% more patients than those that did not.

Read the original post

Outbreak Daily Digest
Biotech Facts & Fallacies
Genetics Unzipped
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...

Gilles-Éric Séralini: Activist professor and face of anti-GMO industry

The French biologist and his research team--funded by the Rodale ...
vandana shiva

Vandana Shiva: ‘Rock Star’ of GMO protest movement has anti-science history

In a 2012 interview, Bill Moyers referred to Vandana Shiva as ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend